Xencor (XNCR) Common Equity (2013 - 2026)
Xencor (XNCR) posted quarterly Common Equity of $515.6 million for Q1 2026, down 19.42% year-over-year from $639.9 million in Q1 2025, and down 18.87% quarter-over-quarter from $635.6 million in Q4 2025.
Analysis
Xencor (XNCR) Common Equity (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Common Equity for 14 consecutive years, with $515.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 19.42% year-over-year to $515.6 million; the TTM figure through Mar 2026 stood at $515.6 million (down 19.42% YoY), while the FY2025 annual figure was $635.6 million, down 5.7% from the prior year.
- Common Equity fell to $515.6 million in Q1 2026 per XNCR's latest filing, from $635.6 million in the prior quarter.
- Across five years, Common Equity topped out at $763.0 million in Q1 2022 and bottomed at $515.6 million in Q1 2026.
- Historically, Common Equity has averaged $659.7 million across 5 years, with a median of $669.0 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity surged 30.74% — and 2026, when it decreased 19.42%.
- Xencor's Common Equity stood at $727.5 million in 2022, then retreated by 8.99% to $662.1 million in 2023, then rose by 1.8% to $674.0 million in 2024, then fell by 5.7% to $635.6 million in 2025, then slipped by 18.87% to $515.6 million in 2026.
- Business Quant data shows XNCR's Common Equity at $515.6 million in Q1 2026, $635.6 million in Q4 2025, and $625.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 503.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 503.23 Mn |
| Mar 31, 2026 | 515.63 Mn |
| Dec 31, 2025 | 635.59 Mn |
| Sep 30, 2025 | 625.32 Mn |
| Jun 30, 2025 | 620.35 Mn |
| Mar 31, 2025 | 639.87 Mn |
| Dec 31, 2024 | 674.03 Mn |
| Sep 30, 2024 | 705.93 Mn |
| Jun 30, 2024 | 548.71 Mn |
| Mar 31, 2024 | 599.73 Mn |
| Dec 31, 2023 | 662.09 Mn |
| Sep 30, 2023 | 669.01 Mn |
| Jun 30, 2023 | 678.88 Mn |
| Mar 31, 2023 | 683.58 Mn |
| Dec 31, 2022 | 727.50 Mn |
| Sep 30, 2022 | 722.70 Mn |
| Jun 30, 2022 | 742.34 Mn |
| Mar 31, 2022 | 763.02 Mn |
| Dec 31, 2021 | 733.50 Mn |
| Sep 30, 2021 | 618.86 Mn |